Skip to content

The impact of shared genetic architecture between schizophrenia and cardiovascular diseases on adverse cardiovascular outcomes

The impact of shared genetic architecture between schizophrenia and cardiovascular diseases on adverse cardiovascular outcomes

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103069
Enrollment
Unknown
Registered
2025-05-23
Start date
2025-05-28
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Schizophrenia patients:None

Sponsors

Peking University Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1 First-episode or relapsed schizophrenia (SCZ) patients who have not received systematic treatment and meet the ICD-10 diagnostic criteria for SCZ; 2 Hospitalized at Peking University Sixth Hospital between May 2024 and November 2025; 3 Aged 18 years or older, with at least one guardian providing care within the past year; 4 Of Han Chinese ethnicity; 5 No anticipated issues related to relocation, transportation difficulties, or access to medical care during the study period; 6 Informed consent obtained from both the patient and their guardian, with signed consent forms.

Exclusion criteria

Exclusion criteria: 1 Presence of physical illnesses such as cardiovascular or cerebrovascular diseases, hypertension, diabetes, or physical disabilities during baseline hospitalization; 2 Presence of any of the following cardiovascular risk factors during baseline hospitalization: fasting low-density lipoprotein cholesterol (LDL-C) >= 4.1 mmol/L or use of lipid-lowering medications; fasting blood glucose >= 6.1 mmol/L or use of glucose-lowering medications; systolic blood pressure >= 140 mmHg or use of antihypertensive medications; 3 Use of antipsychotic medications known to cause hypotensive side effects; 4 Comorbidity with other severe psychiatric disorders, intellectual disability, dementia, or significant cognitive impairment; 5 History of acute dystonia, epilepsy, or febrile convulsions; 6 History of suicide attempts or presence of agitation or excitement symptoms; 7 Severe hepatic or renal dysfunction; 8 Contraindications to antipsychotic treatment; 9 Currently pregnant or breastfeeding; 10 Participation in any interventional clinical trial during baseline hospitalization or follow-up period.

Design outcomes

Primary

MeasureTime frame
Cardiovascular related indicators;

Secondary

MeasureTime frame
Cardiovascular disease;Clinical global impression scale, CGI;

Countries

China

Contacts

Public ContactWeihua Yue

Peking University Sixth Hospital

dryue@bjmu.edu.cn+86 188 1089 8027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026